進行、転移性、進行性結腸直腸癌患者におけるRBS2418の評価 (VISTA-1)
RBS2418のランダム化された二重盲検プラセボ対照研究第2A相試験と、進行、転移性、および進行性結腸直腸癌の被験者における最高の支持ケア(BSC)
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).
調査の概要
詳細な説明
In this Phase 2a study, subjects must have failed, been unable to tolerate, or declined to take known standard-of-care (SOC) therapies. Subjects must have measurable disease per RECIST 1.1, an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2, and predicted life expectancy of greater or equal to 3 months.
Up to approximately 150 subjects will be enrolled and will receive therapy as part of their respective treatment group. Subjects will receive study treatment of RBS2418 or Placebo to Match plus Best Supportive Care with a treatment period consisting of 21-day cycles up to two years or until there is progressive disease (PD), death, withdrawal, or study completion, whichever comes first.
Adverse events (AEs) will be monitored throughout the study and graded in severity according to the guidelines outlined in the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. AEs will be collected until up to 30 days after the end of treatment or until resolution, whichever comes first. Serious Adverse Events (SAEs) will be collected for 90 days after the end of treatment, or if the subject initiates new anti-cancer therapy, then 30 days after the end of treatment, whichever is earlier.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Riboscience Clinical Trials
- 電話番号:(415) 754-3182
- メール:clinicaltrials@riboscience.com
研究場所
-
-
Delaware
-
Newark、Delaware、アメリカ、19718
- 募集
- Christiana Care
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89169
- 募集
- Comprehensive Cancer Centers of Nevada
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology LLC
-
-
Texas
-
Kingwood、Texas、アメリカ、77339
- 募集
- Community Clinical Trials
-
-
-
-
-
San Juan、プエルトリコ、00935
- 募集
- Pan Oncology
-
-
-
-
-
Ho Chi Minh City、ベトナム、715000
- 募集
- Oncology Hospital
-
-
Hanoi
-
Hanoi、Hanoi、ベトナム、10000
- 募集
- Tam Anh, Ha Noi General Hospital
-
-
Ho Chi Minh City
-
Ho Chi Minh City、Ho Chi Minh City、ベトナム、70000
- 募集
- Tam Anh TP. Ho Chi Minh General Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- At least 18 years of age on the day of signing informed consent.
- Male and female subjects with advanced, metastatic, progressive CRC who have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC, as per local SOC treatment regimens. Additionally, subjects must have documented PD based on two scans performed within 2 to 4 months of study initiation.
- Have histologically or cytologically confirmed CRC diagnosis based on pathology report.
- Willing to submit a pre-treatment tissue sample (archival, or fresh tissue if archival is not available).
Exclusion Criteria:
-
Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed:
- Palliative radiotherapy for bone metastases or soft tissue lesions should be completed >7 days prior to the first dose of study treatment.
- Hormone-replacement therapy or oral contraceptives.
- Subjects with Grade 2 neuropathy or Grade 2 alopecia.
-
Subjects with evidence of rapid progression on prior therapy resulting in rapid clinical deterioration.
-
Malignancies other than indications open for enrollment within 3 years prior to Day 1, except for those with negligible risk of metastasis or death treated with expected curative outcome, undergoing active surveillance, or treatment-naïve for indolent tumors.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Group A: EG+ [ENPP1 and cGAS(Cyclic GMP-AMP synthase) positive] RBS2418 plus Best Supportive Care
RBS2418: 200 mg (2 RBS2418 capsules), PO (by mouth), BID (twice a day) plus Best Supportive Care |
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. |
|
プラセボコンパレーター:Group B: EG+ (ENPP1 and cGAS positive) Placebo plus Best Supportive Care
Placebo: 2 placebo capsules, PO, BID plus Best Supportive Care |
Placebo to Match RBS2418 |
|
アクティブコンパレータ:Group C: EG- (ENPP1 and/or cGAS negative) RBS2418 plus Best Supportive Care
RBS2418: 200 mg (2 RBS2418 capsules), PO, BID plus Best Supportive Care |
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. |
|
プラセボコンパレーター:Group D: EG- (ENPP1 and/or cGAS negative) Placebo plus Best Supportive Care
Placebo: 2 placebo capsules, PO, BID plus Best Supportive Care |
Placebo to Match RBS2418 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival
時間枠:From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
|
Time in months from randomization until the first radiographic documentation of objective progression, as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, or death from any cause |
From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
|
|
Overall Survival
時間枠:From randomization until death from any cause, assessed up to 2 years.
|
Time in months from the date of randomization to the date of death from any cause |
From randomization until death from any cause, assessed up to 2 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of Response (DOR)
時間枠:From initial response to disease progression or death, assessed up to 2 years.
|
DOR is defined as the time in months from initial response [when complete response (CR) or partial response (PR) is first determined] to disease progression or death, whichever comes first. |
From initial response to disease progression or death, assessed up to 2 years.
|
|
Disease Control Rate (DCR)
時間枠:From randomization to end of treatment or disease progression, assessed up to 2 years.
|
DCR is defined as the percentage of subjects who achieve a complete response (CR), a partial response (PR) or stable disease (SD). |
From randomization to end of treatment or disease progression, assessed up to 2 years.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。